Description: Surrozen, Inc., a biopharmaceutical company, develops targeted regenerative antibodies to repair a range of tissues and organs damaged by serious disease, and to improve organ function. The company provides antibody platforms that functions as Wnt and R-spondin mimetics in stimulating cell and organ-specific tissue regeneration. Its programs include SZN-043, a liver-specific R-spondin-mimetic to stimulate hepatocyte regeneration in acute and chronic liver disease; and SZN-1326, an intestine-specific Wnt-mimetic to repair diseased epithelial tissue and address an unmet need in patients with inflammatory bowel disease. Surrozen, Inc. was incorporated in 2015 and is based in South San Francisco, California.
Home Page: www.surrozen.com
SRZN Technical Analysis
171 Oyster Point Boulevard
South San Francisco,
CA
94080
United States
Phone:
650 489 9000
Officers
| Name | Title |
|---|---|
| Mr. Craig C. Parker M.B.A. | CEO, Pres & Director |
| Mr. Charles Williams | Chief Financial Officer |
| Dr. Wen-Chen Yeh M.D., Ph.D. | Chief Scientific Officer |
| Dr. K. Christopher Garcia Ph.D. | Co-Founder & Member of Scientific Advisor |
| Dr. Roeland Nusse Ph.D. | Co-Founder & Member of Scientific Advisor |
| Dr. Calvin Kuo M.D., Ph.D. | Co-Founder & Member of Scientific Advisor |
| Ms. Sheela Mohan-Peterson J.D., M.S. | Sr. VP of Legal, Gen. Counsel & Corp. Sec. |
| Dr. Geertrui Vanhove M.B.A., M.D., Ph.D. | Chief Medical Officer |
| Dr. Li Yang Ph.D. | Sr. VP of Biology |
| Ms. Elizabeth Nguyen | Sr. VP and Head of Talent & Culture |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.2138 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2021-01-11 |
| Fiscal Year End: | December |
| Full Time Employees: | 83 |